ABSTRACT
Neuropathic pain represents a diagnostic challenge and is difficult to treat. In recent years, clinical trials have led to the development of a number of new treatment guidelines. The guidelines recommend drugs for the most important types of neuropathic pain and suggest alternatives in the event of lack of effect or intolerable adverse effects. Patients with this condition often suffer from anxiety, depression and insomnia, which influences the choice of drug. This article presents the most important drugs on which these guidelines concur.
Subject(s)
Neuralgia/drug therapy , Adrenergic Uptake Inhibitors/pharmacokinetics , Adrenergic Uptake Inhibitors/therapeutic use , Analgesics/pharmacokinetics , Analgesics/therapeutic use , Analgesics, Opioid/pharmacokinetics , Analgesics, Opioid/therapeutic use , Antidepressive Agents, Tricyclic/pharmacokinetics , Antidepressive Agents, Tricyclic/therapeutic use , Central Nervous System/drug effects , Central Nervous System/physiology , Humans , Neuralgia/physiopathology , Peripheral Nervous System/drug effects , Peripheral Nervous System/physiology , Practice Guidelines as TopicABSTRACT
Although a well-known clinical phenomenon, there still remain some questions regarding the definitions, pathophysiology and epidemiology of early and late poststroke seizures and of poststroke epilepsy. Poststroke seizures and epilepsy constitute important complications in patients surviving a stroke. Several studies of the prevalence and possible predictors of poststroke seizures and epilepsy have been undertaken during the past few decades. Unfortunately, these studies have not consistently used the established definitions. There are only few studies concerning treatment of poststroke epilepsy in the elderly, especially regarding the effect of the newer antiepileptic drugs. The aim of this article is to give an overview of the latest studies of poststroke seizures, with special emphasis on poststroke epilepsy, by presenting data on occurrence, predictors and treatment. The results from the recent studies on both poststroke seizures (early and late) and poststroke epilepsy are quite consistent. Poststroke epilepsy appears to occur in 2-4% of patients. The most convincing predictors of late poststroke seizures and epilepsy and treatment options are discussed in this review.
Subject(s)
Anticonvulsants/therapeutic use , Epilepsy/diagnosis , Epilepsy/therapy , Risk Assessment/methods , Stroke/diagnosis , Stroke/therapy , Epilepsy/epidemiology , Epilepsy/etiology , Humans , Practice Guidelines as Topic , Practice Patterns, Physicians' , Prevalence , Prognosis , Risk Factors , Stroke/complications , Stroke/epidemiologyABSTRACT
PURPOSE: The aims of the study were to assess the occurrence of poststroke epilepsy (PSE) in patients with ischemic strokes, to identify predictors, and to investigate whether treatment in a stroke unit (SU) influenced the long-term outcomes of epilepsy. METHODS: Patients with PSE, defined as those having two ore more unprovoked epileptic seizures > or = 1 week after an ischemic stroke, were identified from a cohort of 484 patients with ischemic strokes. The patients were prospectively assessed 7-8 years after stroke or until death. Different variables were studied to look for possible predictors. RESULTS: From 484 patients with ischemic strokes, PSE developed in 12 (2.5%) and 15 (3.1%) patients during the first year and 7-8 years after stroke, respectively. Eight (53%) of these patients were treated in a stroke unit (SU), and seven (47%) were treated in a general medical ward (GMW). The mean age of those who developed PSE and those who did not was 74.3 years and 76.3 years, respectively. In a multivariate analysis, a Scandinavian Stroke Scale (SSS) score < 30 on admission was a significant predictor for developing PSE [odds ratio (OR), 4.9; p = 0.004). CONCLUSIONS: The prevalence of PSE, 7 to 8 years after an ischemic stroke, was 3.1%. SSS scores < 30 on admission were a significant predictor for PSE. Neither treatment in SU versus GMW, cortical location, nor age at onset of stroke seemed to influence the risk of developing PSE.
